Trial Profile

A Phase 1, Randomized, Double-blind, Placebo-controlled Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered SGB-3383 in Healthy Volunteers

Status: Not yet recruiting

Phase of Trial: Phase I

Latest Information Update: 10 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs SGB 3383 (Primary)
Indications Haemolytic uraemic syndrome; IgA nephropathy; Membranoproliferative glomerulonephritis
Focus Adverse reactions
Sponsors SanegeneBio

05 Jun 2025 New trial record
20 May 2025 According to a SanegeneBio media release, the company has received clinical trial approval from the Center for Drug Evaluation (CDE) under China's National Medical Products Administration (NMPA), for the treatment of complement-mediated kidney diseases, including IgA nephropathy (IgAN), C3 glomerulopathy (C3G), Immune complex-mediated membranoproliferative glomerulonephritis (IC-MPGN), atypical Haemolytic Uraemic Syndrome (aHUS), etc.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com